Proposed accounting treatment of ongoing DHSC dispute in 2021 interim results

Paris, France and Camberley, UK – 16 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the proposed accounting treatment of the ongoing DHSC dispute on its unaudited H1 2021 interim results for the six months ended 30 June 2021. The interim results are expected to be announced on 27 September 2021.